3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

Anti-Purinergic Receptor P2X5
Developed in Rabbit, Affinity Isolated Antibody

Product Number **P 9247**

Product Description

Anti-Purinergic Receptor P2X5 is developed in rabbit using a peptide (C)RENAIVNVKQSQILHPVKT corresponding to residues 437-455 of rat P2X5 as the immunogen. The sequence homology with mouse is 13/18 residues identical. The antibody was affinity isolated on immobilized immunogen.

Anti-Purinergic Receptor P2X5 specifically recognizes purinergic receptor P2X5 protein in rat brain membrane by immunoblotting.

The P2X receptors belong to the ligand-gated ion channel family and are activated by extracellular ATP. The P2X receptors family consists of at least seven isoforms: P2X1-P2X7.[1,2,3] All P2X subunits can assemble to form homomeric or heteromeric functional channels with the exception of P2X6, which only seems to function as part of a heteromeric complex.[4-9] The P2X5R forms a heteromeric receptor with P2X1 receptor, which has distinct properties from the P2X1 or P2X5 homomeric receptors.[4]

In the CNS, P2X receptors are involved in sensory transmission, sensory-motor integration, motor and autonomic control and overall CNS homeostasis.[10] Further, P2X receptors are implicated in modulating cortical plasticity, such as hippocampal plasticity.[11] Recent evidence suggests that P2X receptors in the spinal cord facilitate GABA release and may be important in processing nociceptive information.[12] Peripherally, P2X receptors modulate processes involved in the physiological turnover of squamous epithelial cells[13] and also modulate osteoclasts to stimulate bone resorption.[14]

The P2X receptors in spinal cord may be implicated in the induction or mediation of prolonged persistent pain.[15] Further, there may be a fine balance between function and disease with P2X modulation of cellular proliferation and apoptosis.[16,17] Recent papers suggested possible roles for P2X5 receptor in differentiation and apoptosis in keratinocytes.[18]

Recent advances have allowed researchers to begin to learn about the structure and function of these purinergic receptors. However, much remains to be determined about their precise cellular localization, *in vivo* physiological roles, roles in disease states and possible routes to modulate their structure/function to ameliorate effects of disease.

Reagents

The antibody is supplied lyophilized from phosphate buffered saline, pH 7.4, with 1% bovine serum albumin, and 0.05 % sodium azide as preservative.

Precautions and Disclaimer

Due to the sodium azide content, a material safety data sheet (MSDS) for this product has been sent to the attention of the safety officer of your institution. Consult the MSDS for information regarding hazardous and safe handling.

Preparation Instructions

Reconstitute the lyophilized vial with 0.05 ml or 0.2 ml deionized water, depending on the package size purchased. Antibody dilutions should be made in buffer containing 1% bovine serum albumin.

Storage/Stability

Lyophilized powder can be stored intact at room temperature for several weeks. For extended storage, it should be stored at –20 °C or below. The reconstituted solution can be stored at 4 °C for up to 2 weeks. For longer storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. Storage in “frost-free” freezers is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Centrifuge all antibody preparations before use (10000 x g 5 min). Working dilution samples should be discarded if not used within 12 hours.

Product Profile

The recommended working dilution is (1:200) for immunoblotting.

Note: In order to obtain best results in different techniques and preparations we recommend determining optimal working concentration by titration test.

References

1. Prasad, M., et al., J. Physiol., **573**, 667 (2001).
2. Florenzano, F., et al. Neuroscience, **115**, 425 (2002).
3. Ashcroft, F.M., et al., Ion Channels and Disease Ed 1, (2000).
4. Khakh, B.S., et al., Pharmacol Rev,. **53**, 107 (2001).
5. Ding, Y., et al., J. Auton. Nerv. Syst,. **81**, 289 (2000).
6. Le, K.T., et al., J. Neurosci., **18**, 7152 (1998).
7. Robertson, S.J., et al., Curr. Opin. Neurol., **11**, 378 (2001).
8. Dunn, P.M., et al., Prog. Neurobiol., **65**, 107 (2001).
9. Kim, M., et al., EMBO J., **20**, 6347 (2001).
10. Kanijan, R. et al., J. Comp. Neurol., **407**, 11 (1999).
11. Inoue, K., Pharmacol. Res., **38**, 323 (1998).
12. Hugel, S. and Schlichter, R., J. Neurosci., **20**, 2121(2000).\
13. Groschel-Stewart, U. et al., Cell Tissue Res., **296**, 599 (1999).
14. Naemsch, L.N. et al., J. Cell Sci., **112**, 4425 (1999).
15. Zheng, J.H. and Chen, J., Neurosci. Lett., **7**, 41 (2000).
16. Harada, H. et al., Kidney Int., **57**, 949 (2000).
17. Coutinho-Silva, R. et al., Am. J. Physiol., **276**, C1139 (1999).
18. Greig, A.V., et al., J. Invest. Dermatol., **121,** 1145-1149 (2003).

MCT/PHC 10/04